×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SMMT – summit therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SMMT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/8
04:02 pm
smmt
Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.
4/8
08:03 am
smmt
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
Medium
Report
Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.
3/28
08:08 pm
smmt
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]
Medium
Report
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]
3/28
01:29 am
smmt
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]
3/27
08:15 am
smmt
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Medium
Report
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
3/27
12:22 am
smmt
Akeso Reports Full-Year 2025 Financial Results [Yahoo! Finance]
Low
Report
Akeso Reports Full-Year 2025 Financial Results [Yahoo! Finance]
3/26
05:49 am
smmt
Summit Therapeutics (SMMT) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Summit Therapeutics (SMMT) was upgraded by Truist Financial Corporation to "strong-buy".
3/25
09:38 pm
smmt
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
05:00 pm
smmt
Form DEFA14A Summit Therapeutics Inc.
Neutral
Report
Form DEFA14A Summit Therapeutics Inc.
4/17
04:16 pm
smmt
Form ARS Summit Therapeutics Inc. For: Dec 31
Low
Report
Form ARS Summit Therapeutics Inc. For: Dec 31
4/17
04:12 pm
smmt
Form DEF 14A Summit Therapeutics Inc. For: Apr 17
Low
Report
Form DEF 14A Summit Therapeutics Inc. For: Apr 17
4/6
04:29 pm
smmt
Form PRE 14A Summit Therapeutics Inc. For: Apr 06
Low
Report
Form PRE 14A Summit Therapeutics Inc. For: Apr 06
2/23
04:59 pm
smmt
Form S-8 Summit Therapeutics Inc.
Low
Report
Form S-8 Summit Therapeutics Inc.
2/23
04:10 pm
smmt
Form 10-K Summit Therapeutics Inc. For: Dec 31
Low
Report
Form 10-K Summit Therapeutics Inc. For: Dec 31
2/23
04:08 pm
smmt
Form 8-K Summit Therapeutics Inc. For: Feb 23
Low
Report
Form 8-K Summit Therapeutics Inc. For: Feb 23
1/29
07:35 am
smmt
Form 8-K Summit Therapeutics Inc. For: Jan 29
Medium
Report
Form 8-K Summit Therapeutics Inc. For: Jan 29
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Summit Appoints Robert W. Duggan as Chief Executive Officer
27.7%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
TOP News Decliners
5/1
SUMMIT THERAPEU/S (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
-12.0%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: